Change in Buy Side Allocation of Time: United States 2017/18All-America Research Team July 2, 2019 Related Articles Premium RA Capital Preps New Biotech SPAC — With an Eye on China’s Risks Stephen Taub Biotech Surge Sends Averill to the Top of February’s Market Winners Stephen Taub Optimizing the Efficient Frontier: Opportunistic Credit Amid a Capital Structure Reset Sponsored by Davidson Kempner